Sparrow Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Sparrow Pharmaceuticals is a biopharmaceutical company that focuses on developing treatments for conditions involving excessive corticosteroids. The company was established with the goal of reducing the harmful effects of steroids on patients. By utilizing innovative scientific insights on corticosteroid biology, Sparrow Pharmaceuticals aims to create improved treatment options for disorders like hypercortisolism, as well as to change the way autoimmune and inflammatory conditions are treated. Their main product, SPI-62, is a unique oral medication designed to target the active corticosteroids in key tissues. Founded in 2013 by David A. Katz, Sparrow Pharmaceuticals is located in Portland, Oregon, USA.
Sparrow Pharmaceuticals has raised $217M across 4 funding rounds on record, the most recent a Series B of $95.0M announced in Sep 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Sparrow Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Sep 2025.
Sparrow Pharmaceuticals Funding Rounds
Sparrow Pharmaceuticals raised $50.0M in an undisclosed round announced in May 2021.
2.9 years later, an undisclosed round of $10.2M was announced in Apr 2024.
1.3 years later, an undisclosed round of $61.8M was announced in Jul 2025.
2 months later, a Series B of $95.0M was announced in Sep 2025.
Sparrow Pharmaceuticals Founders and Leadership Team
Contact details for the Sparrow Pharmaceuticals team: 1 of 2 have an email address on file.
Start 14-day free trial →Sparrow Pharmaceuticals Funding Compared to Other Biotechnology Startups
Sparrow Pharmaceuticals' latest round of $95.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Sparrow Pharmaceuticals in Biotechnology and Portland
Companies Similar to Sparrow Pharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Sparrow Pharmaceuticals Funding FAQs
What does Sparrow Pharmaceuticals do?
Sparrow Pharmaceuticals is a biopharmaceutical company that focuses on developing treatments for conditions involving excessive corticosteroids. The company was established with the goal of reducing the harmful effects of steroids on patients. By utilizing innovative scientific insights on corticosteroid biology, Sparrow Pharmaceuticals aims to create improved treatment options for disorders like hypercortisolism, as well as to change the way autoimmune and inflammatory conditions are treated. Their main product, SPI-62, is a unique oral medication designed to target the active corticosteroids in key tissues. Founded in 2013 by David A. Katz, Sparrow Pharmaceuticals is located in Portland, Oregon, USA.
How much funding has Sparrow Pharmaceuticals raised?
Sparrow Pharmaceuticals has raised $217M across 4 rounds on record. The most recent is a Series B of $95.0M announced in Sep 2025.
When did Sparrow Pharmaceuticals last raise funding?
Sparrow Pharmaceuticals' most recent funding round on record is a Series B of $95.0M, announced in Sep 2025.
Who founded Sparrow Pharmaceuticals?
FundedIQ lists David Katz (Founder) at Sparrow Pharmaceuticals.
Who is the CEO of Sparrow Pharmaceuticals?
Robert Jacks is listed as CEO at Sparrow Pharmaceuticals.
Where is Sparrow Pharmaceuticals headquartered?
Sparrow Pharmaceuticals is based in Portland, Oregon, United States.
How many employees does Sparrow Pharmaceuticals have?
Sparrow Pharmaceuticals is in the 11-50 employee band.
How does Sparrow Pharmaceuticals' funding compare to other Biotechnology startups?
Sparrow Pharmaceuticals' latest round of $95.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Sparrow Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Sparrow Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.